Ppp1cb, also known as the beta-type catalytic subunit of serine/threonine-protein phosphatase 1, is involved in multiple biological processes. It participates in the RAS/MAPK pathway as it binds to the RAF1-PPP1CB complex [1]. It also plays a role in hepatic de novo lipogenesis, adipogenesis, and is involved in pathways related to insulin resistance, cancer glycolysis, and chemoresistance in bladder cancer [3,4,5,6,7].

In RASopathies, a de novo PPP1CB variant was identified in a patient with Noonan syndrome, and a recurrent p.Pro49Arg mutation in PPP1CB broadens the clinical phenotype of Noonan-like syndrome [1,2]. In adipogenesis, depletion of PPP1CB in 3T3-L1 preadipocytes suppresses their differentiation into mature adipocytes, suggesting it as a potential therapeutic target for obesity [6,7]. In bladder cancer, gemcitabine plus cisplatin therapy-induced NF-κB signaling promotes OIP5-mediated degradation of PPP1CB, leading to chemoresistance [5].

In conclusion, PPP1CB is crucial in various biological processes and disease conditions. Its role in RASopathies, adipogenesis, and cancer-related chemoresistance, as revealed through these functional studies, provides valuable insights into potential therapeutic strategies for these diseases.